Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

Kensei Tobinai, Takashi Watanabe, Michinori Ogura, Yasuo Morishima, Tomomitsu Hotta, Kenichi Ishizawa, Kuniaki Itoh, Shinichiro Okamoto, Masafumi Taniwaki, Norifumi Tsukamoto, Hirokazu Okumura, Takashi Terauchi, Shigeru Nawano, Masaki Matsusako, Yoshihiro Matsuno, Shigeo Nakamura, Shigeo Mori, Yasuo Ohashi, Masaki Hayashi, Keigo Endo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

There is no data about the efficacy and safety of radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with rituximab-containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90 Y-ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100-149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y-ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five patients (88%) had been pretreated with rituximab, including 27 (68%) pretreated with rituximab-containing chemotherapy. The overall response rate was 83% (33/40; 95% confidence interval, 67-93%), and the complete response rate was 68% (27/40; 95% confidence interval, 51-81%). The overall response rates in patients pretreated with rituximab-containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were 83% (19/23) and 94% (17/18), respectively. The median progression-free survival time of the 40 patients who received 90Y-ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non-hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y-ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B-cell lymphoma, including those pretreated with rituximab-containing chemotherapy.

Original languageEnglish
Pages (from-to)158-164
Number of pages7
JournalCancer Science
Volume100
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

B-Cell Lymphoma
Radioimmunotherapy
Drug Therapy
Confidence Intervals
Vincristine
Prednisone
ibritumomab tiuxetan
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Rituximab
Blood Platelets
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tobinai, K., Watanabe, T., Ogura, M., Morishima, Y., Hotta, T., Ishizawa, K., ... Endo, K. (2009). Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Science, 100(1), 158-164. https://doi.org/10.1111/j.1349-7006.2008.00999.x

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. / Tobinai, Kensei; Watanabe, Takashi; Ogura, Michinori; Morishima, Yasuo; Hotta, Tomomitsu; Ishizawa, Kenichi; Itoh, Kuniaki; Okamoto, Shinichiro; Taniwaki, Masafumi; Tsukamoto, Norifumi; Okumura, Hirokazu; Terauchi, Takashi; Nawano, Shigeru; Matsusako, Masaki; Matsuno, Yoshihiro; Nakamura, Shigeo; Mori, Shigeo; Ohashi, Yasuo; Hayashi, Masaki; Endo, Keigo.

In: Cancer Science, Vol. 100, No. 1, 2009, p. 158-164.

Research output: Contribution to journalArticle

Tobinai, K, Watanabe, T, Ogura, M, Morishima, Y, Hotta, T, Ishizawa, K, Itoh, K, Okamoto, S, Taniwaki, M, Tsukamoto, N, Okumura, H, Terauchi, T, Nawano, S, Matsusako, M, Matsuno, Y, Nakamura, S, Mori, S, Ohashi, Y, Hayashi, M & Endo, K 2009, 'Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma', Cancer Science, vol. 100, no. 1, pp. 158-164. https://doi.org/10.1111/j.1349-7006.2008.00999.x
Tobinai, Kensei ; Watanabe, Takashi ; Ogura, Michinori ; Morishima, Yasuo ; Hotta, Tomomitsu ; Ishizawa, Kenichi ; Itoh, Kuniaki ; Okamoto, Shinichiro ; Taniwaki, Masafumi ; Tsukamoto, Norifumi ; Okumura, Hirokazu ; Terauchi, Takashi ; Nawano, Shigeru ; Matsusako, Masaki ; Matsuno, Yoshihiro ; Nakamura, Shigeo ; Mori, Shigeo ; Ohashi, Yasuo ; Hayashi, Masaki ; Endo, Keigo. / Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. In: Cancer Science. 2009 ; Vol. 100, No. 1. pp. 158-164.
@article{be073c129d0840e39d6e5a6b3fd6b242,
title = "Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma",
abstract = "There is no data about the efficacy and safety of radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with rituximab-containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90 Y-ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100-149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y-ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five patients (88{\%}) had been pretreated with rituximab, including 27 (68{\%}) pretreated with rituximab-containing chemotherapy. The overall response rate was 83{\%} (33/40; 95{\%} confidence interval, 67-93{\%}), and the complete response rate was 68{\%} (27/40; 95{\%} confidence interval, 51-81{\%}). The overall response rates in patients pretreated with rituximab-containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were 83{\%} (19/23) and 94{\%} (17/18), respectively. The median progression-free survival time of the 40 patients who received 90Y-ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non-hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y-ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B-cell lymphoma, including those pretreated with rituximab-containing chemotherapy.",
author = "Kensei Tobinai and Takashi Watanabe and Michinori Ogura and Yasuo Morishima and Tomomitsu Hotta and Kenichi Ishizawa and Kuniaki Itoh and Shinichiro Okamoto and Masafumi Taniwaki and Norifumi Tsukamoto and Hirokazu Okumura and Takashi Terauchi and Shigeru Nawano and Masaki Matsusako and Yoshihiro Matsuno and Shigeo Nakamura and Shigeo Mori and Yasuo Ohashi and Masaki Hayashi and Keigo Endo",
year = "2009",
doi = "10.1111/j.1349-7006.2008.00999.x",
language = "English",
volume = "100",
pages = "158--164",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

AU - Tobinai, Kensei

AU - Watanabe, Takashi

AU - Ogura, Michinori

AU - Morishima, Yasuo

AU - Hotta, Tomomitsu

AU - Ishizawa, Kenichi

AU - Itoh, Kuniaki

AU - Okamoto, Shinichiro

AU - Taniwaki, Masafumi

AU - Tsukamoto, Norifumi

AU - Okumura, Hirokazu

AU - Terauchi, Takashi

AU - Nawano, Shigeru

AU - Matsusako, Masaki

AU - Matsuno, Yoshihiro

AU - Nakamura, Shigeo

AU - Mori, Shigeo

AU - Ohashi, Yasuo

AU - Hayashi, Masaki

AU - Endo, Keigo

PY - 2009

Y1 - 2009

N2 - There is no data about the efficacy and safety of radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with rituximab-containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90 Y-ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100-149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y-ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five patients (88%) had been pretreated with rituximab, including 27 (68%) pretreated with rituximab-containing chemotherapy. The overall response rate was 83% (33/40; 95% confidence interval, 67-93%), and the complete response rate was 68% (27/40; 95% confidence interval, 51-81%). The overall response rates in patients pretreated with rituximab-containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were 83% (19/23) and 94% (17/18), respectively. The median progression-free survival time of the 40 patients who received 90Y-ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non-hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y-ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B-cell lymphoma, including those pretreated with rituximab-containing chemotherapy.

AB - There is no data about the efficacy and safety of radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with rituximab-containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90 Y-ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100-149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y-ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five patients (88%) had been pretreated with rituximab, including 27 (68%) pretreated with rituximab-containing chemotherapy. The overall response rate was 83% (33/40; 95% confidence interval, 67-93%), and the complete response rate was 68% (27/40; 95% confidence interval, 51-81%). The overall response rates in patients pretreated with rituximab-containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were 83% (19/23) and 94% (17/18), respectively. The median progression-free survival time of the 40 patients who received 90Y-ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non-hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y-ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B-cell lymphoma, including those pretreated with rituximab-containing chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=58149284058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149284058&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.00999.x

DO - 10.1111/j.1349-7006.2008.00999.x

M3 - Article

C2 - 19018755

AN - SCOPUS:58149284058

VL - 100

SP - 158

EP - 164

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -